MSI Dx Analysis System for Lynch Syndrome Screening

Promega Corporation has launched its OncoMate MSI Dx Analysis System in vitro diagnostic (IVD) in the U.S., giving oncologists and pathologists a new option to screen for Lynch syndrome in patients with colorectal cancer. OncoMate MSI was cleared by the US FDA as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.

OncoMate MSI IVD features fluorescent, multiplex PCR-based fragment-sizing test; high sensitivity and specificity—targets five mononucleotide repeat markers; short turn-around time—from FFPE sample to answer in as little as 10 hours; and conserves samples–MSI results with ≤1 FFPE section.

Promega Corp.

www.promega.com

This site uses Akismet to reduce spam. Learn how your comment data is processed.